Scarica l'app Stockscreener
1.52
3.80%
-0.06
Pre-mercato:
1.53
0.01
+0.66%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché SONN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.58
Aprire:
$1.6
Volume 24 ore:
108.22K
Relative Volume:
0.08
Capitalizzazione di mercato:
$4.57M
Reddito:
$129.20K
Utile/perdita netta:
$-7.44M
Rapporto P/E:
-0.1358
EPS:
-11.19
Flusso di cassa netto:
$-8.62M
1 W Prestazione:
-14.61%
1M Prestazione:
-16.02%
6M Prestazione:
-78.20%
1 anno Prestazione:
-85.82%
Intervallo 1D:
$1.50
$1.60
Intervallo di 1 settimana:
$1.50
$1.76
Portata 52W:
$1.41
$18.72
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Nome
Sonnet Biotherapeutics Holdings Inc
Settore
Industria
Telefono
609-375-2227
Indirizzo
100 OVERLOOK CENTER, PRINCETON, NJ
Confronta SONN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.52 | 4.57M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.66 | 106.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.87 | 75.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.60 | 39.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.51 | 31.02B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.43 | 26.95B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sonnet Biotherapeutics Holdings Inc Borsa (SONN) Ultime notizie
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - GlobeNewswire
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Corporate UpdateOn December 17, 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, released it - Defense World
Insights into Sonnet BioTherapeutics Q4 Earnings - Benzinga
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Sonnet BioTherapeutics Slashes Operating Costs 37% in FY2024, Advances Cancer Drug Pipeline - StockTitan
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Sonnet BioTherapeutics (NASDAQ: SONN) Announces $3.9 Million Registered Direct Offering and Private PlacementPrinceton, New Jersey, December 9, 2024 – Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company focusing on targeted i - Defense World
Sonnet BioTherapeutics (NASDAQ: SONN) Reports Positive Safety Data in SON-1010 Monotherapy Dose Escalation Trial - Defense World
Sonnet BioTherapeutics reports progress in cancer trial By Investing.com - Investing.com Nigeria
Sonnet BioTherapeutics reports progress in cancer trial - Investing.com India
Sonnet BioTherapeutics Announces $3.9 Million Registered - GlobeNewswire
Sonnet BioTherapeutics Secures $3.9M Strategic Financing Deal Through Mixed Securities Offering - StockTitan
Sonnet BioTherapeutics Announces Topline Safety Data - GlobeNewswire
Sonnet Bio's Cancer Drug Shows Promise: 48% Disease Control, One Patient's Tumor Shrinks 45% in Phase 1 Trial - StockTitan
Sonnet BioTherapeutics Advances in SON-1010 Phase 1 Trial - TipRanks
Sonnet BioTherapeutics reports advances in cancer treatment drug By Investing.com - Investing.com Canada
Sonnet BioTherapeutics reports advances in cancer treatment drug - Investing.com India
Sonnet BioTherapeutics Announces Publication Detailing the - GlobeNewswire
Sonnet BioTherapeutics Unveils Breakthrough Cancer Drug Delivery System in Major Publication - StockTitan
Sonnet BioTherapeutics Holdings (STU:H3D) Financial Strengt - GuruFocus.com
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Sonnet BioTherapeutics’ $5 Million Common Stock Offering - Global Legal Chronicle
Sonnet BioTherapeutics Holdings (STU:H3D) Change In Receiva - GuruFocus.com
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire
Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan
Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World
Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology
Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia
SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia
Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz
Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire
Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India
Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK
Sonnet BioTherapeutics Raises $5M in Stock Offering with Warrant Coverage | SONN Stock News - StockTitan
Sonnet BioTherapeutics secures patent for cancer drug candidates - Investing.com India
U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn
Sonnet BioTherapeutics Secures Patent for Cancer Drugs - TipRanks
Sonnet BioTherapeutics Announces Issuance of U.S. Patent - GlobeNewswire
Sonnet BioTherapeutics Secures Key Patent for Novel Cancer Immunotherapy Drugs | SONN Stock News - StockTitan
Sonnet stock tumbles 22% in wake of proposed offering filing - MSN
(SONN) On The My Stocks Page - Stock Traders Daily
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top ViewsHealthcare Triangle (NASDAQ:HCTI) - Benzinga
When (SONN) Moves Investors should Listen - Stock Traders Daily
Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance - Stocks Telegraph
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance - TipRanks
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq - GlobeNewswire
SONN (Sonnet BioTherapeutics Holdings) Capex-to-Operating-C - GuruFocus.com
Sonnet BioTherapeutics Enters into Licensing Agreement with Alkem Laboratories for DPN in India - Chemical Industry Digest
Sonnet Biotherapeutics Holdings Inc Azioni (SONN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.13%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):